The addition of an anti-angiogenic, vascular endothelial growth factor (VEGF) inhibitor sorafenib, to TACE has been experimented in the recent past to increase the OS and TTP in HCC patients. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.